Hematological findings and complications of COVID-19

Evangelos Terpos1, Ioannis Ntanasis-Stathopoulos1, Ismail Elalamy2,3, Efstathios Kastritis1,

Theodoros N. Sergentanis1, Marianna Politou4, Theodora Psaltopoulou1, Grigoris

Gerotziafas2,3, Meletios A. Dimopoulos1

Affiliations: 1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University

of Athens, Athens, Greece;

2
Thrombosis Center, Service d’Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires de l’Est

Parisien, Assistance Publique Hôpitaux de Paris, Paris, France.

3
Research Group "Cancer, Haemostasis and Angiogenesis", INSERM U938, Centre de Recherche Saint-

Antoine, Institut Universitaire de Cancérologie, Faculty of Medicine, Sorbonne University, Paris, France.
4
Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National and Kapodistrian

University of Athens, Athens, Greece;

Correspondence:

Evangelos Terpos, Department of Clinical Therapeutics, School of Medicine, National and

Kapodistrian University of Athens, Alexandra General Hospital, 80 Vas. Sofias Avenue

11528, Athens, Greece. Tel.:+30-213-216-2846, Fax:+30-213-216-2511,

e-mail: [email protected]; [email protected]

Conflict of interest: No relevant conflict of interest to declare

Running title: COVID-19 and blood disorders

This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as doi:
10.1002/ajh.25829

This article is protected by copyright. All rights reserved.

Abstract

COVID-19 is a systemic infection with a significant impact on the hematopoietic system and

hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with

prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may

also have prognostic value in determining severe cases. During the disease course,

longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including

LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt

intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and

ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability

is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently

reported, whereas their gradual increase during disease course is particularly associated with

disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin

degradation products increase, with severe thrombocytopenia lead to life-threatening

Disseminated intravascular coagulation (DIC) which necessitates continuous vigilance and

prompt intervention. COVID-19 infected patients whatever hospitalized or ambulatory are at

high risk for VTE and an early and prolonged pharmacological thromboprophylaxis with low

molecular weight heparin is highly recommended. Last but not least, the need for assuring

blood donations during the pandemic is also highlighted.

Keywords: SARS-CoV-2; COVID-19; Coronavirus; Lymphocytes; Coagulation

This article is protected by copyright. All rights reserved.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus

disease 2019 (COVID-19) has rapidly evolved from an epidemic outbreak in Wuhan, China1

into a pandemic infecting more than one million individuals all over the world, whereas

billions of citizens are affected by measures of social distancing and the socioeconomic

impact of the pandemic. SARS-CoV-2 is approximately 80% similar to SARS-CoV and

invades host human cells by binding to the angiotensin-converting enzyme 2 (ACE2)

receptor.1Although it is well documented that COVID-19 is primarily manifested as a

respiratory tract infection, emerging data indicate that it should be regarded as a systemic

disease involving multiple systems including cardiovascular, respiratory, gastrointestinal,

neurological, hematopoietic and immune system.2-4 Mortality rates of COVID-19 are lower

than SARS and Middle East Respiratory Syndrome (MERS);5 however, COVID-19 is more

lethal than seasonal flu. Older people and those with comorbidities are at increased risk of

death from COVID-19, but younger people without major underlying diseases may also

present with potentially lethal complications such as fulminant myocarditis and disseminated

intravascular coagulopathy (DIC).6, 7

Herein, we summarize the numerous hematologic

findings and complications of COVID-19 and we provide guidance for early prevention and

management of the latter.

Full Blood Count and Biochemistry Findings: Correlation with Prognosis

During the incubation period, usually ranging from 1 to 14 days, and during the early phase

of the disease, when non-specific symptoms are present, peripheral blood leukocyte and

This article is protected by copyright. All rights reserved.

lymphocyte counts are normal or slightly reduced. Following viremia, SARS-CoV-2

primarily affects the tissues expressing high levels of ACE2 including the lungs, heart and

gastrointestinal tract. Approximately 7 to 14 days from the onset of the initial symptoms,

there is a surge in the clinical manifestations of the disease with a pronounced systemic

increase of inflammatory mediators and cytokines, which may even be characterized as a

“cytokine storm”.8 At this point, significant lymphopenia becomes evident. Although more

in-depth research on the underlying etiology is necessary, several factors may contribute to

COVID-19 associated lymphopenia. It has been shown that lymphocytes express the ACE2

receptor on their surface;9 thus SARS-CoV-2 may directly infect those cells and ultimately

lead to their lysis. Furthermore, the cytokine storm is characterized by markedly increased

levels of interleukins (mostly IL-6, IL-2, IL-7, granulocyte colony stimulating factor,

interferon-γ inducible protein 10, MCP-1, MIP1-a) and tumor necrosis factor (TNF)-alpha,

which may promote lymphocyte apoptosis.10-12 Substantial cytokine activation may be also

associated with atrophy of lymphoid organs, including the spleen, and further impairs

lymphocyte turnover.13 Coexisting lactic acid acidosis, which may be more prominent among

cancer patients who are at increased risk for complications from COVID-19,14 may also

inhibit lymphocyte proliferation.15 Table 1 presents the results of main studies regarding

lymphopenia in COVID-19.

Guan et al. provided data on the clinical characteristics of 1,099 COVID-19 cases with

laboratory confirmation during the first two months of the epidemic in China.16 On

admission, the vast majority of patients presented with lymphocytopenia (83.2%), whereas

36.2% had thrombocytopenia, and 33.7% showed leukopenia. These hematological

This article is protected by copyright. All rights reserved.

abnormalities were more prominent among severe versus non-severe cases (96.1% versus

80.4% for lymphocytopenia, 57.7% versus 31.6% for thrombocytopenia and 61.1% versus

28.1% for leukopenia). These results were consistent in four other descriptive studies that

were conducted during the same period in China and included 41, 99, 138 and 201 confirmed

cases with COVID-19, respectively.17-20 Specifically, Huang et al.,17 and Wang et al.19

highlighted an association between lymphopenia and need of ICU care, whereas Wu et al.20

showed an association between lymphopenia and acute respiratory distress syndrome

(ARDS) development. Specifically, Wu et al retrospectively analyzed possible risk factors

for developing ARDS and death among 201 patients with COVID-19 pneumonia in Wuhan,

China.20 Increased risk of ARDS during the disease course was significantly associated with

increased neutrophils (p<0.001), decreased lymphocytes (p<0.001) in a bivariate Cox

regression analysis. Increased neutrophils (p=0.03) were associated with increased risk of

death.20

Furthermore, lymphopenia and was also documented in approximately 40% of the first 18

hospitalized patients with COVID-19 in Singapore.21 A more recent report on 69 patients

confirmed the percentage of those with lymphocytopenia, whereas 20% had mild

thrombocytopenia.22 Interestingly, 69% of patients with a low lymphocyte count showed a

reactive lymphocyte population including a lymphoplasmacytoid subset, which was not

common in the peripheral blood of patients with SARS infection in 2003.22-24 Flow cytometry

did not reveal any inversion in the CD4+/CD8+ lymphocyte ratio.22 However, functional

studies have suggested that SARS-CoV-2 may impair the function of CD4+ helper and

This article is protected by copyright. All rights reserved.

regulatory T-cells and promote the initial hyperactivation which is followed by rapid

exhaustion of cytotoxic CD8+ T-cells.25, 26

In Singapore, Fan et al. also found that patients requiring ICU support had significantly

lower lymphocyte levels (p<0.001) at baseline.22 In another retrospective study including 52

critically ill patients from Wuhan, China, lymphopenia was reported in 85% of patients.27

Lymphopenia was also prominent among critically ill patients with COVID-19 in

Washington, USA.28, 29
During hospitalization, non-survivors demonstrated a more

significant deterioration in lymphopenia compared with those who survived (p<0.05).19 It has

also been reported that patients with severe disease and fatal outcomes present with a

decreased lymphocyte/white blood cell ratio both in admission (p<0.001) and during

hospitalization (p<0.001) compared with those who survived.26, 30 Contrary to non-survivors,

survivors demonstrated a nadir of lymphocytes count on day 7 from symptom onset and a

subsequent restoration.31 Therefore, serial assessment of lymphocyte count dynamics may be

predictive of patient outcome. Tan et al have proposed a model based on lymphocyte counts

at two time points; patients with less than 20% lymphocytes at days 10-12 from the onset of

symptoms and less than 5% at days 17-19 have the worst prognosis.32

Recent studies have shown that myocardial injury among inpatients with COVID-19 is

associated with increased mortality.33, 34 In a prospective study in Wuhan, China including

416 consecutive patients 82 (19.7%) had documented myocardial injury. Compared with the

others, these patients with myocardial injury had higher leukocyte (p<0.001), lower

lymphocyte (p<0.001) and lower platelet counts (p<0.001).33A retrospective study including

187 patients with COVID-19 from another hospital in Wuhan showed that patients with high

This article is protected by copyright. All rights reserved.

troponin-T levels had leukocytosis (p<0.001), increased neutrophils (p<0.001) and decreased

lymphocytes (p=0.01).34

A meta-analysis of nine studies has suggested that thrombocytopenia is significantly

associated with the severity of the COVID-19 disease, with very high between-studies

heterogeneity though; a more sizeable drop in platelet counts was noted especially in non-

survivors.35 Table 2 shows the results of main studies examining platelet counts in COVID-

19 disease.

Interestingly, Qu et al showed that among 30 hospitalized patients with COVID-19, those

presenting with a peak in the platelet count during the disease course had worse outcomes.36

Interestingly, the platelet to lymphocyte ratio at the time of platelet peak emerged as an

independent prognostic factor for prolonged hospitalization in the multivariate analysis. It

was suggested that a high platelet to lymphocyte ratio may indicate a more pronounced

cytokine storm due to enhanced platelet activation.36

The emerging role of biomarkers procalcitonin, ferritin and C-reactive protein in the

prognosis

Table 3 summarizes the results of studies on CRP, procalcitonin and ferritin in COVID-19

disease. In the study by Guan et al.16, presenting results from various provinces in China,

interesting biochemical findings were described; C-reactive protein (CRP) was elevated in

60.7% of patients, elevated procalcitonin, which may also be suggestive of a secondary

bacterial infection complicating the clinical course of tCOVID-19 disease, was found in 5.5%

and elevated lactate dehydrogenase (LDH) in 41% of patients. More severe cases showed a

This article is protected by copyright. All rights reserved.

more marked increase compared with the non-severe ones (81.5% versus 56.4% for CRP,

13.7% versus 3.7% for procalcitonin and 58.1% versus 37.2% for LDH).16

Accordingly in a retrospective cohort study including 191 patients with COVID-19 from

Wuhan, China, non-survivors, as compared with survivors, presented more often with high

LDH (p<0.0001), high procalcitonin (p<0.0001), increased serum ferritin levels (p=0.0008)

and elevated IL-6 (p<0.0001).31 In the study by Wang et al., 40% of patients presented with

elevated LDH.19 Increased LDH has been associated also with higher risk of ARDS20, ICU

support22 and death 20, 31 across published studies.

Higher CRP has been linked to unfavorable aspects of COVID-19 disease, such as ARDS

development20, higher troponin-T levels and myocardial injury,33 and death.30 A meta-

analysis of four published studies showed that increased procalcitonin values were associated

with a nearly 5-fold higher risk of severe infection (OR=4.76; 95% CI: 2.74-8.29, I2=34%) 37.

Regarding ferritin, Wu et al. showed that higher serum ferritin was associated with ARDS

development (HR=3.53, 95%CI: 1.52-8.16, p=0.003); the trend of an association with

survival did not reach significance (HR=5.28, 95%CI: 0.72-38.48, p=0.10).20 At their

univariate analysis, Zhou et al. supported an association between higher serum ferritin levels

and death, but no multivariate analysis was presented.31

Another emerging biomarker for COVID-19 course is interleukin-6 (IL-6). In the study by

Chen et al. 52% (51/99) of patients had elevated IL-6 levels at admission.18 Increased IL-6

levels have been associated with increased risk of death,20 and a gradual increase during

hospitalization has been reported in non-survivors.31

This article is protected by copyright. All rights reserved.

Coagulation Complications

Coagulation disorders are relatively frequently encountered among COVID-19 patients,

especially among those with severe disease.30, 31 In a multicenter retrospective study during

the first two months of the epidemic in China, 260 out of 560 patients (46.4%) with

laboratory confirmed COVID-19 infection had elevated D-dimer (≥0.5 mg/L), whereas the

elevation was more pronounced among severe cases (59.6% versus 43.2% for non-severe

ones).16 D-dimer dynamics can reflect the severity and their increased levels are associated

with adverse outcomes among patients with community-acquired pneumonia.38Accordingly,

elevated D-dimer (> 1.5 μg/L) was detected in 36% of patients in a descriptive study of 99

COVID-19 cases in Wuhan, China.18 Another retrospective study in China including 41

patients showed that D-dimer and prothrombin time (PT) levels were higher on admission

among patients requiring ICU support (median D-dimer 2.4 mg/L for ICU versus 0.5 mg/L

for non-ICU, p=0.0042; median PT 12.2 sec for ICU versus 10.7 sec, p=0.012).17 In the study

by Wang et al, which was previously described, patients requiring ICU treatment had

significantly higher D-dimers (p<0.001) compared with less severe cases.19

Patients presenting with cardiac injury in the context of COVID-19 infection are more

prone to coagulation disorders compared with those without cardiac involvement (p=0.02).33

Patients with high troponin-T levels may present more frequently with elevated PT

(p=0.005), activated partial thromboplastin time (APTT) (p=0.003), and D-dimer

(p<0.001).34 Among 201 patients with COVID-19 pneumonia, increased PT was associated

with increased risk of ARDS (p<0.001), whereas increased levels of D-dimer were

significantly associated with increased risk of ARDS (p<0.001) and death (p=0.002).20 The

This article is protected by copyright. All rights reserved.

difference in median levels of D-dimer between survivors and non-survivors was larger than

that between the ARDS and non-ARDS groups, which might suggest that DIC-related

complications may have led a subset of patients to death independently of ARDS. In a

multicenter retrospective cohort study from China, increased D-dimer levels (>1μg/mL) were

significantly associated with in-hospital death in the multivariable analysis (p=0.003).31

Interestingly, D-dimer levels showed a sequential increase in time among non-survivors

compared with those who survived (p<0.05).19, 31In another retrospective study by Tang et al,

encompassing data from 183 consecutive patients with COVID-19, non-survivors had

significantly higher D-dimer (p<0.05), fibrin degradation products (FDP) levels (p<0.05), and

prolonged PT (p<0.05) and APTT (p<0.05) compared with survivors at initial evaluation. By

the late hospitalization, the fibrinogen and AT levels were also significantly lower in

non‐survivors .6 Interestingly, 71.4% of non-survivors versus 0.6% of survivors fulfilled the

clinical criteria for disseminated intravascular coagulation (DIC) during the disease course.

The median time from admission to DIC manifestation was 4 days (range: 1-12 days).6 In a

prospective study evaluating the coagulation profile of patients with COVID-19, D-dimer,

FDP, and fibrinogen levels were markedly higher among patients compared with healthy

controls (p<0.001 for all three comparisons). Patients with severe disease showed higher

values of D-dimer and FDP than those with milder manifestation (p<0.05 for both

comparisons).39

All the above indicate that D-dimer elevation and DIC may be common in patients with

severe form of COVID-19 infection, a fact that, despite methodological limitations, became

evident in a meta-analysis of four published studies (Table 4).40 Immune deregulation and

This article is protected by copyright. All rights reserved.

endothelial dysfunction may be actively implicated in the underlying pathophysiology,41

which remains to be elucidated in future studies.

The scoring system for compensated and overt DIC endorsed by the International Society

on Thrombosis and Haemostasis should be followed for early DIC identification.42 A

proposed treatment algorithm for managing patients with COVID-19 and DIC is shown in the

Figure.

VTE risk in hospitalized COVID-19 patients is an emerging issue. The rate of symptomatic

VTE in acutely ill hospitalized medical patients raises up to 10%.43 Prolonged immobilization

during illness, dehydration, an acute inflammatory state, presence of other cardiovascular risk

factors (i.e., hypertension, diabetes, obesity) or cardiovascular disease (i.e., coronary artery

disease, history of ischemic stroke or peripheral artery disease), previous history of VTE and

classical genetic thrombophilia, such as heterozygous Factor V Leiden mutation are common

comorbidities in hospitalized COVID-19 patients, which potentially increase VTE risk. The

possibility of endothelial cell activation/damage due to the virus binding to ACE2 receptor

may further increase VTE risk. The release of a large amount of inflammatory mediators and

the application of hormones and immunoglobulins in severe or critically ill patients may lead

to an increased blood viscosity. Furthermore, mechanical ventilation, central venous

catheterization, and surgery may induce vascular endothelial damage. The combination of all

the above factors may lead to DVT occurrence or even the possibility of lethal PE due to

thrombus migration. Thus, facing such VTE risk, the application of pharmacological

thromboprophylaxis is mandatory in hospitalized COVID-19 patients. In this context, VTE

risk increase must be assessed in all acutely ill patients admitted to hospital, and

This article is protected by copyright. All rights reserved.

thromboprophylaxis should be given to all these high-risk patients according to current

clinical practice guidelines.44

The use of Risk Assessment Models (RAM) such as IMPROVE -VTE in internal medicine

department may be helpful. The modified IMPROVE-VTE RAM which includes the D-

Dimers levels together with other clinical predictors of VTE enhances the precision of that

score for the identification of high VTE risk patients eligible for an adapted pharmacological

thromboprophylaxis.45 Moreover, it is also important to pay attention to VTE risk in

asymptomatic or ambulatory patients with mild COVID-19 infection. Early diagnosis of PE

in COVID-19 patients with clinical manifestations of sudden deterioration of oxygenation,

respiratory distress, or hypotension is of major importance for the improvement of the

clinical outcomes. Although the published data are very limited, it seems reasonable that D-

dimer evaluation as well as the kinetics of their increase could offer a useful information for

the research of DVT and/or PE, along with the recommended imaging techniques such as

ultrasound venous echo-doppler or bedside echocardiography. A recent small study in 25 PE

suspected patients explored with Computed Tomography Pulmonary Angiography (CTPA)

showed that those with confirmed PE (n=10) had D-dimer levels higher than 7000 ng/ml

compared to those without PE with significantly lower D-dimer levels.46

Low molecular weight heparins (LMWH), or unfractionated heparin (UFH) should be

preferred over direct oral anticoagulants (DOACs) due to possible drug-drug interactions

with concomitant antiviral (especially anti-HIV protease inhibitors such as ritonavir) and

antibacterial (such as azithromycin) treatment.47 Such treatments interfering with CYP3A4

This article is protected by copyright. All rights reserved.

and/or P-gp pathways may increase the bleeding risk or reduce the antithrombotic effect in

case of DOAC use.

In a retrospective Chinese study, including 449 severe COVID-19 patients in Wuhan,

LMWH administration among patients with markedly elevated D-dimers or in those meeting

the criteria for sepsis-induced DIC was significantly associated with improved 28-day overall

survival, p=0.017 and p=0.029 for the two patient groups, users versus non-users,

respectively.48 Furthermore, clinicians should routinely evaluate all COVID-19 patients under

heparin treatment for indices of heparin-induced thrombocytopenia (HIT) syndrome

performing the 4T score (thrombocytopenia, timing of platelet count fall, thrombosis or other

sequalae, other causes for thrombocytopenia). Although HIT incidence in this patient group

has not been determined yet, there is potentially an increased risk due to the immune

deregulation and the massive inflammatory syndrome induced by the viral infection, with

significant neutrophil extracellular traps (NETS) and platelet factor 4 (PF4) release.

In summary, there are four important aspects in the management of COVID-patients : 1)

early diagnosis and follow-up of DIC, by applying the ISTH score (platelet count, PT,

fibrinogen, D-dimer, antithrombin and protein C activity monitoring) which can determine

prognosis and guide more appropriate critical care support); 2) identification of patients at

high risk whatever hospitalized or ambulatory; 3) optimization of thromboprophylaxis

regimen and LMWH are the first line choice drug, and 4) the anti-inflammatory properties of

LMWH may be an added benefit in COVID 19 patients and the possible need of integrating

other antithrombotic treatments such as antithrombin, and recombinant thrombomodulin that

may be also helpful in this complex ‘immunothrombosis’ process.

This article is protected by copyright. All rights reserved.

Blood and hematopoietic stem cell donation

Last but not least, it is of outmost importance to consider the impact of the COVID-19

pandemic on the availability of blood products. Worldwide, insecurity and anxiety of being

infected by SARS-CoV-2 along with measures of social isolation largely prevent blood

donations.49 Similarly, the pandemic crisis may hinder the donation of hematopoietic stem

cells, as well.50 However, the need for stem cell donors will remain constant and the need for

blood donor will probably increase in order to support the critically ill COVID-19 patients.

Therefore, the authorities should reformulate the infrastructure and apply all necessary safety

precautions to prevent viral transmission. Effective public awareness campaigns on the

importance of maintaining an adequate national blood supply, need for blood donors, and

safety of the donation process should be disseminated continuously.51 Furthermore, they

should inform and educate the younger about the priceless role of blood donation and the life-

saving value of hematopoietic stem cell donation. All of us should become aware of our

collective responsibility and contribute to the well-being of the members of our society.

Concluding remarks

In conclusion, COVID-19 disease has prominent manifestations from the hematopoietic

system and is often associated with a major blood hypercoagulability. Careful evaluation of

laboratory indices at baseline and during the disease course can assist clinicians in

formulating a tailored treatment approach and promptly provide intensive care to those who

are in greater need. Preventive measures for thromboprophylaxis and early identification of

This article is protected by copyright. All rights reserved.

potentially lethal complications including DIC in order to effectively intervene will improve

patient outcomes, and will probably reduce the death rate overall and among infected patients

without significant comorbidities. Continuous vigilance is necessary and urgent studies have

to be planned to define whether optimal anticoagulation regimen with or without adjunctive

antithrombotic therapies (e.g., LMWH, antithrombin or thrombomodulin) may be helpful in

patients with COVID-19.

This article is protected by copyright. All rights reserved.

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia
in China, 2019. N Engl J Med 2020 Feb 20; 382(8): 727-733.

2. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for

Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019
(COVID-19) Pandemic. J Am Coll Cardiol 2020 Mar 18.

3. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern.
Lancet Gastroenterol Hepatol 2020 Mar 20.

4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm

syndromes and immunosuppression. Lancet 2020 Mar 28; 395(10229): 1033-1034.

5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the

Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24.

6. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with

poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020 Apr;
18(4): 844-847.

7. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of

Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol 2020 Mar 27.

8. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients.

Emerg Microbes Infect 2020 Dec; 9(1): 687-690.

9. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on

the epithelial cells of oral mucosa. Int J Oral Sci 2020 Feb 24; 12(1): 8.

10. Singh S, Sharma A, Arora SK. High producer haplotype (CAG) of -863C/A, -308G/A
and -238G/A polymorphisms in the promoter region of TNF-alpha gene associate with
enhanced apoptosis of lymphocytes in HIV-1 subtype C infected individuals from North
India. PLoS One 2014; 9(5): e98020.

11. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces
production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J
Immunol 2002 Oct 15; 169(8): 4288-4297.

12. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-alpha-induced apoptosis in

lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of
caspases. J Immunol 1999 Feb 15; 162(4): 2154-2161.

This article is protected by copyright. All rights reserved.

13. Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological
manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model:
implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020 Mar 26.

14. You B, Ravaud A, Canivet A, et al. The official French guidelines to protect patients
with cancer against SARS-CoV-2 infection. Lancet Oncol 2020 Mar 25.

15. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic
acid on human T cells. Blood 2007 May 1; 109(9): 3812-3819.

16. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
China. N Engl J Med 2020 Feb 28.

17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 2020 Feb 15; 395(10223): 497-506.

18. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99

cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet
2020 Feb 15; 395(10223): 507-513.

19. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With

2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7.

20. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
China. JAMA Intern Med 2020 Mar 13.

21. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical
Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020 Mar 3.

22. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with
COVID-19 infection. Am J Hematol 2020 Mar 4.

23. Chng WJ, Lai HC, Earnest A, Kuperan P. Haematological parameters in severe acute
respiratory syndrome. Clin Lab Haematol 2005 Feb; 27(1): 15-20.

24. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in
Hong Kong. N Engl J Med 2003 May 15; 348(20): 1986-1994.

25. Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced
functional diversity of T cells in peripheral blood may predict severe progression in COVID-
19 patients. Cell Mol Immunol 2020 Mar 17.

This article is protected by copyright. All rights reserved.

26. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with
COVID-19 in Wuhan, China. Clin Infect Dis 2020 Mar 12.

27. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
study. Lancet Respir Med 2020 Feb 24.

28. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill
Patients With COVID-19 in Washington State. JAMA 2020 Mar 19.

29. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in
the Seattle Region - Case Series. N Engl J Med 2020 Mar 30.

30. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of
coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J
(Engl) 2020 Mar 20.

31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar
28; 395(10229): 1054-1062.

32. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-
19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5: 33.

33. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in
Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020 Mar 25.

34. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of

Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020 Mar 27.

35. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe

coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020
Mar 13; 506: 145-148.

36. Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with

prognosis in patients with coronavirus disease-19. J Med Virol 2020 Mar 17.

37. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019
(COVID-19): A meta-analysis. Clin Chim Acta 2020 Mar 4; 505: 190-191.

38. Snijders D, Schoorl M, Schoorl M, Bartels PC, van der Werf TS, Boersma WG. D-
dimer levels in assessing severity and clinical outcome in patients with community-acquired
pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med 2012 Jul;
23(5): 436-441.

This article is protected by copyright. All rights reserved.

39. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with
SARS-CoV-2 infection. Clin Chem Lab Med 2020 Mar 16.

40. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease
2019: A Pooled Analysis. Thromb Haemost 2020.

41. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV

pneumonia. J Thromb Haemost 2020 Apr; 18(4): 786-787.

42. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC
from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013
Feb 4.

43. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 Feb; 141(2 Suppl):
e195S-e226S.

44. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018
guidelines for management of venous thromboembolism: optimal management of
anticoagulation therapy. Blood Adv 2018 Nov 27; 2(22): 3257-3291.

45. Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and
Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical
Population for Extended Thromboprophylaxis. TH Open 2020 Jan; 4(1): e59-e65.

46. Chen J, Wang X, Zhang S, et al. Findings of acute pulmonary embolism in COVID-
19 patients. Lancet Infect Dis 2020; [in press].

47. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and
management of coagulopathy in COVID‐19. J Thromb Haemost 2020.

48. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated

with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J
Thromb Haemost 2020 Mar 27.

49. Pagano MB, Hess JR, Tsang HC, et al. Prepare to adapt: Blood supply and
transfusion support during the first 2 weeks of the 2019 Novel Coronavirus (COVID-19)
pandemic affecting Washington State. Transfusion 2020 Mar 21.

50. Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on

the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone
Marrow Transplant 2020 Mar 23.

This article is protected by copyright. All rights reserved.

51. WHO. Maintaining a safe and adequate blood supply during the pandemic outbreak of
coronavirus disease (COVID-19). WHO reference number: WHO/2019-
nCoV/BloodSupply/2020.1. World Health Organization 2020.

This article is protected by copyright. All rights reserved.

Figure legends

Figure. A proposed treatment algorithm for managing patients with COVID-19 and DIC.

This article is protected by copyright. All rights reserved.

Accepted Article
 First author Region Study period Sample Categorisation of Main findings
(year) size haematological factors

16
Accepted Article

Guan (2020) 552 hospitals in 30 December 11, 1099 Lymphocytopenia: Lymphocytopenia was present in 83.2% of patients on
provinces, 2019 - January 31, lymphocyte count of less admission. 92.6% (50/54) of patients with the composite
3
autonomous 2020 than 1500 cells/mm primary endpoint (admission to an intensive care unit, use of
regions, and mechanical ventilation, or death) presented with
municipalities in lymphocytopenia vs. 82.5% (681/825) of patients without the
a
mainland China primary endpoint (p=0.056 ). Severe cases presented
lymphocytopenia more frequently (96.1%, 147/153) vs. non-
a
severe cases (80.4%, 584/726); p<0.001
17
Huang (2020) Jinyintan Hospital, December 16, 41 Low lymphocyte count of 85% (11/13) of patients needing ICU care presented low
9
Wuhan, China 2019, to January <1.0 x10 lymphocytes per lymphocyte count vs. 54% (15/28) of patients that did not need
2, 2020 litre ICU care (p=0.045).
19
Wang (2020) Zhongnan Hospital, January 1 to 138 Lymphocytes treated as a ICU cases presented with lower lymphocyte count (median:0.8,
9
Wuhan, China February 3, 2020 continuous variable, x10 IQR: 0.5-0.9) vs. non-ICU cases (median: 0.9, IQR: 0.6-1.2);
per L p=0.03. Longitudinal decrease was noted in non-survivors.
20
Wu (2020) Jinyintan Hospital, December 25, 201 Lymphocytes treated as a Lower lymphocyte count was associated with ARDS
9
Wuhan, China 2019, to February continuous variable, x10 development (HR=0.37, 95%CI: 0.21-0.63, p<0.001 in the
13, 2020 /mL in a bivariate Cox incremental model); the association with survival did not reach
regression model significance (HR=0.51, 95%CI: 0.22-1.17, p=0.11)
21
Young (2020) 4 hospitals in January 23 to 18 Lymphocytes treated as a Lymphopenia was present in 7 of 16 patients (39%). Median
9
Singapore February 3, 2020 continuous variable, x10 lymphocyte count was 1.1 (IQR: 0.8-1.7) in patients that
per L; lymphopenia was required supplemental O2 and 1.2 (IQR:0.8-1.6) in those that
9
defined as <1.1 ×10 /L. did not; no statistical comparison was undertaken.
22
Fan (2020) National Centre for January 23 to 69 Lymphopenia: lymphocyte Lymphopenia at admission (4/9 of ICU patients vs. 1/58 non-

This article is protected by copyright. All rights reserved.

 9
Infectious Diseases, February 28, 2020 count of <0.5 ×10 /L. ICU patients, p<0.001) and nadir lymphopenia during hospital
Singapore stay (7/9 of ICU patients vs. 1/58 non-ICU patients, p<0.001)
were associated with need for ICU.
27
Yang (2020) Jinyintan Hospital, December 24, 52 Lymphocytes treated as a Lymphocytopenia occurred in 44 (85%) of critically ill patients,
Accepted Article

Wuhan, China 2019, to February critically continuous variable with no significant difference between survivors and non-
9
9, 2020 ill (×10 /L); lymphocytopenia survivors. A numeric difference in lymphocyte count was noted
patients presented but not defined in non-survivors vs. survivors (0.62 vs.0.74).
31
Zhou (2020) Jinyintan Hospital December 25, 191 Lymphocyte counts Lower lymphocyte count was associated with higher odds of
and Wuhan 2019, to January treated as a continuous death at the univariate analysis (OR=0.02, 95%CI: 0.01-0.08;
9
Pulmonary 31, 2020 variable (×10 /L) in a p<0.0001); at the multivariate analysis, the finding lost
Hospital, Wuhan, multivariate logistic significance (OR=0.19, 95%CI: 0.02-1.62; p=0.13)
China regression model
28
Arentz (2020) Evergreen Hospital, February 20, 21 ICU Low lymphocyte count Low lymphocyte count was noted in 14/21 (67%) of critically ill
Washington State, 2020, to March 5, patients (less than 1000 cells/μL) patients.
USA 2020

Bhatraju Seattle region, February 24, 24 ICU Lymphocyte counts Lymphocytopenia was common (75% of patients), with a
29 3
(2020) Washington State, 2020, to March 9, patients presented as a continuous median lymphocyte count of 720 per mm (IQR: 520 to 1375).
USA 2020 variable; definition of
lymphocytopenia was not
provided
30
Deng (2020) Wuhan, China Tongji Hospital January 1, Lymphocyte counts On admission, patients in the death group exhibited
and Hankou 2020 to treated as a continuous significantly lower lymphocyte count (median: 0.63, IQR: 0.40-
9 9 9
branch of Central February variable (×10 /L) 0.79) ×10 /L vs. 1.00, IQR: 0.72- 1.27 ×10 /L, p < 0.001).
Hospital of 21, 2020 Patients in the death group also exhibited lower
Wuhan, China lymphocyte/WBC ratio (median: 7.10, IQR: 4.45, 12.73% vs.
23.5, IQR: 15.27-31.25%, p<0.001). The lymphocyte/WBC ratio
continued to decrease during hospitalization.

This article is protected by copyright. All rights reserved.

 32
Tan (2020) General Hospital of Not reported 90 Lymphocytes at two time Lymphocytes <20% on day 10-12 signal a pre-severe disease
Central Theater patients points: day 10-12 from and lymphocytes <5% on day 17-19 denote a critical illness.
Command, Wuhan, at the symptom onset (>20% or
China validation <20%) and day 17-19
cohort (>20%, 5-20% and <5%).
Accepted Article

Table 1. Studies and main findings for lymphocyte count in Covid-19 patients.
a
p-values calculated by Terpos et al., on the basis of contingency tables (Pearson’s chi-squared test) in articles that did not present formal statistical comparisons; ARDS:
acute respiratory distress syndrome; IQR: interquartile range.

This article is protected by copyright. All rights reserved.

 First Region Study period Sample Categorisation of Main findings
author size haematological factors
(year)
Guan 552 hospitals in 30 December 11, 1099 Thrombocytopenia was Thrombocytopenia was present in 36.2% of patients on admission. 46.6%
Accepted Article

16
(2020) provinces, 2019 - January defined as a platelet count (27/58) of patients with the composite primary endpoint (admission to an
3
autonomous 31, 2020 of less than 150,000/mm intensive care unit, use of mechanical ventilation, or death) presented with
regions, and thrombocytopenia vs. 35.5% (288/811) of patients without the primary
a
municipalities in endpoint (p=0.091 ). Severe cases presented thrombocytopenia more
a
mainland China frequently (57.7%, 90/156) vs. non-severe cases (31.6%, 225/713); p<0.001
Huang Jinyintan Dec 16, 2019, to 41 Low platelet count of <100 8% (1/13) of patients needing ICU care presented low platelet count vs. 4%
17 9
(2020) Hospital (Wuhan, Jan 2, 2020 x10 platelets per litre (1/27) of patients that did not need ICU care (p=0.45).
China)
Wang Zhongnan Hospital, January 1 to 138 Platelets treated as a No significant difference (p=0.78) was noted in platelet count between ICU
19 9
(2020) Wuhan, February 3, continuous variable, x10 cases (median:142, IQR: 119-202) vs. non-ICU cases (median: 165, IQR: 125-
China 2020 per L 188); p=0.78.
20
Wu (2020) Jinyintan December 25, 201 Platelets treated as a Platelet counts did not differ between patients with ARDS vs. those without
9
Hospital, Wuhan, 2019, to continuous variable, x10 ARDS (difference: -4.00, 95%CI: −27.00 to +20.00, p=0.73). Accordingly, no
China February 13, /mL significant difference was noted in dead vs. alive ARDS patients (p=0.10).
2020
Young 4 hospitals in January 23 to 18 Platelets treated as a Median platelet count was 156 (IQR: 116-217) in patients that required
21 9
(2020) Singapore February 3, continuous variable , x10 supplemental O2 and 159 (IQR: 128-213) in those that did not; no statistical
2020 per L comparison was undertaken.
22
Fan (2020) National Centre for January 23 to 69 Low platelet count: Low platelets were not associated with ICU care either at admission
9
Infectious February 28, platelet of <100 ×10 /L. (p=0.67) or as a nadir during hospital stay (p=0.69)
Diseases, Singapore 2020
Yang Jinyintan December 24, 52 Platelets treated as a Platelet count noted in non-survivors was 191 (63) and 164 (74) in survivors;
27
(2020) Hospital, Wuhan, 2019, to critically continuous variable no statistical tests were presented.
9
China February 9, ill (×10 /L)
2020 patients
Arentz Evergreen Hospital, February 20, 21 ICU Platelets presented as a Mean baseline platelet count was 235 (ranging between 52 and 395),
28 9
(2020) Washington State, 2020, to March patients continuous variable whereas the reference range was 182-369 × 10 /L
9
USA 5, 2020 (×10 /L)

This article is protected by copyright. All rights reserved.

 Bhatraju Seattle region, February 24, 24 ICU Platelet counts presented Median of lowest platelet count was 180,000 (IQR: 109,000–257,000)
29
(2020) Washington State, 2020, to March patients as a continuous variable
3
USA 9, 2020 (cells per mm )
Zhou Jinyintan December 25, 191 Platelets treated as a Median platelet count was lower in non-survivors (165.5, IQR: 107.0–229.0)
31
(2020) Hospital and Wuhan 2019, to January continuous variable vs. survivors (220.0, IQR: 168.0–271.0), p<0.0001
Accepted Article

9
Pulmonary Hospital, 31, 2020 (×10 /L)
Wuhan, China
Lippi Meta-analysis of Studies 9 Platelets treated as a Platelet count was significantly lower in patients with more severe COVID-
35 9 9
(2020) published studies published up to published continuous variable 19 (WMD -31×10 /L, 95% CI, -35 to -29×10 /L), with very high heterogeneity
2
March 06, 2020 studies (I =92%). A more substantial drop in platelets was observed in non-
survivors
36
Qu (2020) Huizhou Municipal January 2020 to 30 Platelet to lymphocyte PLR at peak of platelets was associated with severe cases (mean±SD:
Central Hospital, February 2020 ratio (PLR) 626.27±523.64 vs. 262.35±97.78 in non-severe cases, p=0.001). Higher PLR
China of patients during treatment was also associated with longer hospitalization,
on average.

Table 2. Studies and main findings for platelet count (and platelet to lymphocyte ratio) in Covid-19 patients.
a
p-values calculated by Terpos et al., on the basis of contingency tables (Pearson’s chi-squared test) in articles that did not present formal statistical comparisons; ARDS:
acute respiratory distress syndrome; IQR: interquartile range.

This article is protected by copyright. All rights reserved.

 Studied First Region Study period Sample Categorisation of Main findings
parameters author size haematological
(year) factors
CRP
Guan 552 hospitals in 30 December 11, 1099 Elevated CRP ≥10 Disease severity was associated with elevated CRP;
Accepted Article

16
(2020) provinces, 2019 - January mg/liter 81.5% (110/135) of severe cases vs. 56.4% (371/658) of
autonomous 31, 2020 non-severe cases presented with elevated CRP
a
regions, and (p<0.001 ). The primary composite endpoint
municipalities in (admission to an intensive care unit, use of mechanical
mainland ventilation, or death) was also associated with elevated
a
China CRP (41/45, 91.1% vs. 440/748, 58.8%, p<0.001 ).
20
Wu (2020) Jinyintan December 25, 201 hs-CRP >5 vs. ≤5 Higher hs-CRP was associated with ARDS development
Hospital, Wuhan, 2019, to mg/L in a bivariate (HR=4.81, 95%CI: 1.52-15.27, p=0.008).
China February 13, Cox regression
2020 model
Young 4 hospitals in January 23 to 18 CRP treated as a Median CRP level was 65.6 (IQR: 47.5-97.5) in patients
21
(2020) Singapore February 3, continuous variable that required supplemental O2 and 11.1 (IQR: 0.9-19.1)
2020 , mg/ L in those that did not; no statistical comparison was
undertaken.
Deng Wuhan, China Tongji January CRP treated as a On admission, patients in the death group exhibited
30
(2020) Hospital and 1, 2020 continuous variable significantly higher CRP level (median: 109.25, IQR:
Hankou to mg/ L) 35.00-170.28 mg/L vs. median: 3.22 IQR: 1.04, 21.80
branch of February mg/L, p＜0.001). CRP levels remained high after
Central 21, 2020 treatment in the non-survivors.
Hospital of
Wuhan, China
Ferritin
20
Wu (2020) Jinyintan December 25, 201 Serum ferritin >300 Higher serum ferritin was associated with ARDS
Hospital, Wuhan, 2019, to vs. ≤300 ng/mL in a development (HR=3.53, 95%CI: 1.52-8.16, p=0.003); the
China February 13, bivariate Cox trend of an association with survival did not reach
2020 regression model significance (HR=5.28, 95%CI: 0.72-38.48, p=0.10).
Zhou Jinyintan December 25, 191 Serum ferritin >300 Higher serum ferritin levels were associated with higher
31
(2020) Hospital and 2019, to vs. ≤300 ng/mL in a odds of death at the univariate analysis (OR=9.10,

This article is protected by copyright. All rights reserved.

 Wuhan Pulmonary January 31, multivariate logistic 95%CI: 2.04-40.58; p=0.0038); a multivariate analysis
Hospital, Wuhan, 2020 regression model was not presented.
China
Procalcitonin
Guan 552 hospitals in 30 December 11, 1099 Elevated Disease severity was associated with elevated
Accepted Article

16
(2020) provinces, 2019 - January procalcitonin ≥0.5 procalcitonin; 13.7% (16/117) of severe cases vs. 3.7%
autonomous 31, 2020 ng/ml (19/516) of non-severe cases presented with elevated
a
regions, and procalcitonin (p<0.001 ). The primary composite
municipalities in endpoint (admission to an intensive care unit, use of
mainland mechanical ventilation, or death) was also associated
China with elevated procalcitonin (12/50, 24.0% vs. 23/583,
a
3.9%, p<0.001 ).
Huang Jinyintan Dec 16, 2019, 41 Elevated 3/12 (25%) patients necessitating ICU care presented
17
(2020) Hospital (Wuhan, to Jan 2, 2020 procalcitonin ≥0.5 with elevated procalcitonin levels vs. 0/27 non-ICU
China) ng/ml patients. Overall, procalcitonin levels was higher in ICU
vs. non-ICU patients (p=0.031).
Wang Zhongnan Hospital, January 1 to 138 Elevated 75% (27/36) of ICU patients presented with high
19
(2020) Wuhan, February 3, procalcitonin ≥0.05 procalcitonin vs. 21.6% (22/102) of non-ICU patients
China 2020 ng/ml (p<0.001).
Zhou Jinyintan December 25, 191 Procalcitonin Higher serum procalcitonin levels were associated with
31
(2020) Hospital and 2019, to treated as higher odds of death at the univariate analysis
Wuhan Pulmonary January 31, continuous variable (OR=13.75, 95%CI: 1.81-104.40; p=0.011); a
Hospital, Wuhan, 2020 (in ng/mL) in a multivariate analysis was not presented.
China multivariate logistic
regression model
Arentz Evergreen Hospital, February 20, 21 ICU Procalcitonin Mean baseline procalcitonin was 1.8 (ranging between
28
(2020) Washington State, 2020, to patients presented as a 0.12-9.56 ng/mL), whereas the reference range was
USA March 5, 2020 continuous variable 0.15-2.0 ng/mL
(ng/mL)
Lippi Meta-analysis of Studies 4 The definition of Increased procalcitonin values were associated with a
35
(2020) published studies published up published increased nearly 5-fold higher risk of severe infection (OR=4.76;
2
to March 03, articles procalcitonin during 95% CI: 2.74-8.29, I =34%)
2020 the synthesis of
studies was not

This article is protected by copyright. All rights reserved.

 declared.
Table 3. Studies and main findings for biomarkers related to inflammation (CRP, ferritin, procalcitonin) in Covid-19 patients.
a
p-values calculated by Terpos et al., on the basis of contingency tables (Pearson’s chi-squared test) in articles that did not present formal statistical comparisons; ARDS:
acute respiratory distress syndrome; IQR: interquartile range.
Accepted Article

This article is protected by copyright. All rights reserved.

 First author Region Study Sample size Categorisation of Main findings
(year) period haematological
factors
16
Guan (2020) 552 hospitals in December 1099 Elevated D-dimer: Patients with the composite primary endpoint (admission to an
Accepted Article

30 provinces, 11, 2019 - ≥0.5 mg/litre intensive care unit, use of mechanical ventilation, or death) presented
autonomous January with elevated D-dimer more frequently: 69.4% (34/49) vs. 44.2%
a
regions, and 31, 2020 (226/511; p=0.001 ). Accordingly, severe cases presented elevated D-
municipalities in dimer more frequently (59.6%, 65/109) vs. non-severe cases (43.2%,
a
mainland 195/451); p=0.002
China
17
Huang (2020) Jin Yintan Dec 16, 41 D-dimer treated as a Patients necessitating ICU care presented with higher D-dimer levels
Hospital (Wuhan, 2019, to continuous variable, (median: 2.4; IQR: 0.6-14.4) vs. non-ICU patients (median: 0.5, IQR:
China) Jan 2, 2020 in mg/L 0.3-0.8), p=0.0042.
19
Wang (2020) Zhongnan January 1 138 D-dimer treated as a ICU cases presented with higher D-dimer level (median:414, IQR: 191-
Hospital, Wuhan, to continuous variable, 1324) vs. non-ICU cases (median: 166, IQR: 101-285); p<0.001.
China February in mg/L Longitudinal increase was noted in non-survivors.
3, 2020
20
Wu (2020) Jinyintan December 201 D-dimer treated as a Higher D-dimer level was associated with ARDS development
Hospital, Wuhan, 25, 2019, continuous variable (HR=1.03, 95%CI: 1.01-1.04, p<0.001) and poor survival (HR=1.02,
China to (μg/mL) in a 95%CI: 1.01-1.04, p=0.002) in the incremental models.
February bivariate Cox
13, 2020 regression model
31
Zhou (2020) Jinyintan December 191 D-dimer greater Higher D-dimer was associated with higher odds of death (OR=18.42,
Hospital and 25, 2019, than 1 μg/mL in a 95%CI: 2.64–128.55; p=0.0033)
Wuhan to January multivariate logistic
Pulmonary 31, 2020 regression model
Hospital, Wuhan,
China
40
Lippi (2020) Meta-analysis of Studies 553 (4 D-dimer treated as a D-dimer values were considerably higher in COVID-19 patients
published studies published published continuous variable; with severe disease than in those without (WMD= 2.97mg/L;
up to studies) the definition of 95% CI: 2.47–3.46 mg/L). However, heterogeneity across synthesized
2
March 04, COVID-19 disease studies was very high (I =94%).

This article is protected by copyright. All rights reserved.

 2020 severity was not
provided during the
synthesis of studies
Table 4. Studies and main findings for D-dimer in Covid-19 patients.
a
Accepted Article

p-values calculated by Terpos et al., on the basis of contingency tables (Pearson’s chi-squared test) i articles that did not present formal statistical comparisons; ARDS:
acute respiratory distress syndrome; IQR: interquartile range; WMD: weighted mean difference.

This article is protected by copyright. All rights reserved.